Chris Viehbacher, new Chairman of PhRMA made the point to his audience that "regulatory risk" is among the steepest hurdles facing the biopharmaceutical industry in the US.
Viehbacher specifically cited the FDA and the need for the agency to stay abreast of the rapidly evolving science of new drugs from a regulatory perspective. "We need predictability from the agency" -- presumably in the evaluation and approval process.
Viehbacher said PhRMA will focus on the 3 T's going forward: transparency, truth and trust. "We have allies. We don't have a lot of them but we have them. They're not going to be interested in earnings per share."
Posted by Bruce Lehr April 14th 2011.